

Supplemental Figures S1 and S2

Cell-free DNA variant sequencing using plasma and AR-V7 testing of CTCs in prostate cancer patients

Verena Lieb^{1,2}, Amer Abdulrahman^{1,2}, Katrin Weigelt^{1,2}, Siegfried Hauch³, Michael Gombert³, Juan Guzman^{1,2}, Laura Bellut^{1,2}, Peter J. Goebell^{1,2}, Robert Stöhr^{2,4}, Arndt Hartmann^{2,4}, Bernd Wullich^{1,2}, Helge Taubert^{1,2,†,*} and Sven Wach^{1,2,†}




Figure S1A: Classification of called variants in cfDNA according to their known functional impact




Figure S1B: Classification of called variants in cfDNA according to variation type




Figure S2: Frequency of pathogenic and likely pathogenic variants per sequence range for the top 15 genes